Biotechnology Investor Advisory Service
Who do we offer this service to?
We offer biotechnology advisory service to venture capital firms and private investors. This advisory service pertains to the quality of the underlying science of the project only. We do not offer financial advice.
Why do we offer this service?
Venture capital firms are not the endangered species that require protection. In a world where a late night bathroom tweet can swing the markets, there are worse ways to generate revenue than helping institutional investors understand the science behind a project.
We help in the following ways:
- We communicate biomedical science to the potential investors from a neutral perspective. Startups seeking funding will only focus on the positive aspects with optimistic forward looking statements. We are here to help you find the balanced view.
- By helping investors better see whether the project in question has solid science, we indirectly help other projects with better scientific foundations.
- Our service helps you navigate a recurring pattern among some biotech startups. Founders with strong credentials and networking skills can attract early-stage investment even when their ventures are still developing. Once the initial funding round is completed, these founders may move on to launch new projects, continuing the cycle with fresh ideas and opportunities.
When you work with Grantigen, you will better understand the pros and cons of the science behind a biotechnology startup project. We provide an unbiased view. Our in-depth analysis of the technology is extremely helpful for anyone who is not well-versed in biomedical sciences.
Many venture capital firms have the ability to analyze the potential value of the underlying science to some degree. In one notable experience, a successful first round of funding came from the venture capital firm that had no expertise in biotech whatsoever but rather needed to diversity the large funds under management. They were comfortable investing in the biotech startup because of:
- Pre-determined percentage of allocation of funds to the most risky ventures such as biotechnology and
- Extraordinary social skills of the people who pitched the idea to the investors.
After over a decade, the biotech startup has not met its objectives, in spite of the venture capital firm directed millions of dollars toward the effort. They could have used our service to find a better project.